Hypertension Pipeline Progresses: 100+ Therapies Pushing Innovation - DelveInsight | Merck/Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics

Fueled by relentless research, the Hypertension pipeline is witnessing transformative developments, with key players accelerating breakthroughs in treatment.

DelveInsight's "Hypertension Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Hypertension market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Hypertension drugs, the Hypertension pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension Pipeline analysis depicts a robust space with 80+ active players working to develop 100+ pipeline drugs for Hypertension treatment.
• The leading Hypertension companies include Merck/Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharm/Liquidia, Merck Sharp & Dohme, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Sumitomo Pharma (Enzyvant Therapeutics), Cereno Scientific, AstraZeneca, Nicox/Kowa, Qlaris Bio, Noveome Biotherapeutics, SciPharm Sarl, Cereno Scientific AB, and others are evaluating their lead assets to improve the Hypertension treatment landscape.
• Key Hypertension pipeline therapies in various stages of development include Sotatercept (MK-7962), Ralinepag, YUTREPIA (inhaled treprostinil), Imatinib (TNX-201), Vardenafil (RT234), Seralutinib (GB002), L606 (liposomal treprostinil), MK-5475, AV-101 (dry powder inhaled imatinib), Treprostinil Palmitil (TPIP) (INS1009), LTP001, VASCULAN (ifetroban), Rodatristat Ethyl, CS1, LYNPARZA (olaparib), NCX 470, QLS-111, ST266, Treprostinil, CS1, and others.
• In Jan 2025, Mineralys Therapeutics, Inc. announced that the FDA approved its IND application for a Phase 2 clinical trial to evaluate lorundrostat for treating obstructive sleep apnea (OSA) and hypertension. The trial is scheduled to begin in Q1 2025.
• In November 2024, Medtronic announced that it has received the Centers for Medicare & Medicaid Services (CMS) transitional pass-through (TPT) payment for the Symplicity Spyral renal denervation (RDN) catheter. Effective January 1, 2025, this TPT payment will be applicable under the Medicare Hospital Outpatient Prospective Payment System for the catheter used in the Symplicity blood pressure procedure. This decision enhances patient access to the hypertension treatment device, which has also received breakthrough device designation from the U.S. Food and Drug Administration (FDA).
• In August 2024, Merck announced that the European Commission approved WINREVAIRTM (sotatercept) for use in combination with other therapies to treat pulmonary arterial hypertension (PAH) in adult patients with WHO Functional Class II to III. WINREVAIR, the first activin signaling inhibitor therapy for PAH, was approved across all 27 EU member states, Iceland, Liechtenstein, and Norway. The approval is based on positive safety and efficacy results from the Phase 3 STELLAR trial.
• In August 2024, Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has granted tentative approval for YUTREPIATM (treprostinil) inhalation powder. This treatment is designed for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). While YUTREPIA has met all FDA requirements for safety, quality, and efficacy, final approval is pending the expiration of regulatory exclusivity for a competing product.

Request a sample and discover the recent breakthroughs happening in the Hypertension pipeline landscape @ https://www.delveinsight.com/report-store/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypertension Overview
Hypertension, or high blood pressure, is a chronic condition where elevated arterial pressure increases the risk of heart disease, stroke, kidney damage, and vision loss. It is classified as primary (with no clear cause) or secondary (due to underlying conditions like kidney disease or hormonal disorders). Often called the "silent killer," hypertension may remain asymptomatic for years, though severe cases can cause headaches, dizziness, shortness of breath, or chest pain.
Its pathology involves vascular dysfunction, oxidative stress, inflammation, and neurohumoral imbalances, particularly within the renin-angiotensin-aldosterone system (RAAS). Treatment combines lifestyle changes-healthy diet (e.g., DASH), exercise, weight management, and reduced sodium and alcohol intake-with medications to control blood pressure and prevent complications.

Find out more about Hypertension medication @ https://www.delveinsight.com/report-store/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypertension Treatment Analysis: Drug Profile
Seralutinib: Gossamer Bio
Seralutinib, an inhaled therapy by Gossamer Bio, is in Phase III development for pulmonary arterial hypertension (PAH). It targets multiple receptors, including PDGFRα, PDGFRβ, CSF1R, and c-KIT, to reduce inflammation and vascular remodeling associated with PAH.

AD-209: Addpharma Inc.
AD-209, developed by Addpharma Inc., is an investigational treatment for hypertension. It is part of a broader pipeline addressing conditions like hyperlipidemia and diabetes. Currently, it is in Phase III development for hypertension.

Zilebesiran: Alnylam Therapeutics
Zilebesiran, an RNA interference (RNAi) therapeutic by Alnylam Therapeutics, is in Phase II development for hypertension. It inhibits angiotensinogen (AGT) synthesis in the liver, reducing angiotensin II levels and promoting sustained blood pressure reduction.

Key Hypertension Therapies and Companies
• Sotatercept (MK-7962): Merck/Bristol Myers Squibb
• Ralinepag: United Therapeutics
• YUTREPIA (inhaled treprostinil): Liquidia Technologies
• Imatinib (TNX-201): Tenax Therapeutics
• Vardenafil (RT234): Respira Therapeutics
• Seralutinib (GB002): Gossamer Bio
• L606 (liposomal treprostinil): Pharmosa Biopharm/Liquidia
• MK-5475: Merck Sharp & Dohme
• AV-101 (dry powder inhaled imatinib): Aerovate Therapeutics
• Treprostinil Palmitil (TPIP) (INS1009): Insmed
• LTP001: Novartis
• VASCULAN (ifetroban): Cumberland Pharmaceuticals
• Rodatristat Ethyl: Sumitomo Pharma (Enzyvant Therapeutics)
• CS1: Cereno Scientific
• LYNPARZA (olaparib): AstraZeneca
• NCX 470: Nicox/Kowa
• QLS-111: Qlaris Bio
• ST266: Noveome Biotherapeutics
• Treprostinil: SciPharm Sarl
• CS1: Cereno Scientific AB

Learn more about the novel and emerging Hypertension pipeline therapies @ https://www.delveinsight.com/report-store/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hypertension Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Hypertension Pipeline Report
• Coverage: Global
• Key Hypertension Companies: Merck/Bristol Myers Squibb, United Therapeutics, Liquidia Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharm/Liquidia, Merck Sharp & Dohme, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Sumitomo Pharma (Enzyvant Therapeutics), Cereno Scientific, AstraZeneca, Nicox/Kowa, Qlaris Bio, Noveome Biotherapeutics, SciPharm Sarl, Cereno Scientific AB, and others.
• Key Hypertension Pipeline Therapies: Sotatercept (MK-7962), Ralinepag, YUTREPIA (inhaled treprostinil), Imatinib (TNX-201), Vardenafil (RT234), Seralutinib (GB002), L606 (liposomal treprostinil), MK-5475, AV-101 (dry powder inhaled imatinib), Treprostinil Palmitil (TPIP) (INS1009), LTP001, VASCULAN (ifetroban), Rodatristat Ethyl, CS1, LYNPARZA (olaparib), NCX 470, QLS-111, ST266, Treprostinil, CS1, and others.

Dive deep into rich insights for drugs used for Hypertension treatment; visit @ https://www.delveinsight.com/report-store/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hypertension Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hypertension Pipeline Therapeutics
6. Hypertension Pipeline: Late-Stage Products (Phase III)
7. Hypertension Pipeline: Late-Stage Products (Phase III)
8. Hypertension Pipeline: Mid-Stage Products (Phase II)
9. Hypertension Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.